These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32297656)
1. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy. Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656 [TBL] [Abstract][Full Text] [Related]
2. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases. Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554 [TBL] [Abstract][Full Text] [Related]
3. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259 [TBL] [Abstract][Full Text] [Related]
4. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863 [TBL] [Abstract][Full Text] [Related]
5. Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. Tan HY; Wang N; Zhang C; Chan YT; Yuen MF; Feng Y Hepatology; 2021 Jun; 73(6):2326-2341. PubMed ID: 33068461 [TBL] [Abstract][Full Text] [Related]
6. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. Rada M; Kapelanski-Lamoureux A; Petrillo S; Tabariès S; Siegel P; Reynolds AR; Lazaris A; Metrakos P Commun Biol; 2021 Aug; 4(1):950. PubMed ID: 34376784 [TBL] [Abstract][Full Text] [Related]
7. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution. Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028 [TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model. Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126 [TBL] [Abstract][Full Text] [Related]
9. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. van Dam PJ; van der Stok EP; Teuwen LA; Van den Eynden GG; Illemann M; Frentzas S; Majeed AW; Eefsen RL; Coebergh van den Braak RRJ; Lazaris A; Fernandez MC; Galjart B; Laerum OD; Rayes R; Grünhagen DJ; Van de Paer M; Sucaet Y; Mudhar HS; Schvimer M; Nyström H; Kockx M; Bird NC; Vidal-Vanaclocha F; Metrakos P; Simoneau E; Verhoef C; Dirix LY; Van Laere S; Gao ZH; Brodt P; Reynolds AR; Vermeulen PB Br J Cancer; 2017 Nov; 117(10):1427-1441. PubMed ID: 28982110 [TBL] [Abstract][Full Text] [Related]
10. Clinical implications and mechanism of histopathological growth pattern in colorectal cancer liver metastases. Kong BT; Fan QS; Wang XM; Zhang Q; Zhang GL World J Gastroenterol; 2022 Jul; 28(26):3101-3115. PubMed ID: 36051338 [TBL] [Abstract][Full Text] [Related]
11. High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern. Fan S; Fleischer JR; Dokshokova L; Böhme LS; Haas G; Schmitt AM; Gätje FB; Rosen LE; Bohnenberger H; Ghadimi M; Cui B; Xu X; Kalucka JM; Bösch F; De Oliveira T; Conradi LC Mol Ther Oncol; 2024 Sep; 32(3):200828. PubMed ID: 39072289 [TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures. Illemann M; Eefsen RH; Bird NC; Majeed A; Osterlind K; Laerum OD; Alpízar-Alpízar W; Lund IK; Høyer-Hansen G Mol Carcinog; 2016 Feb; 55(2):193-208. PubMed ID: 25594187 [TBL] [Abstract][Full Text] [Related]
13. [Value of histopathological growth pattern in predicting 3-year progression free survival after operation in patients with liver metastasis of colorectal cancer]. Zhang YL; He HJ; Cheng J; Shen DH Zhonghua Bing Li Xue Za Zhi; 2021 Jan; 50(1):26-31. PubMed ID: 33396983 [No Abstract] [Full Text] [Related]
14. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550 [TBL] [Abstract][Full Text] [Related]
15. Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53. Shao J; Lu J; Zhu W; Yu H; Jing X; Wang YL; Wang X; Wang XJ Cell Death Differ; 2019 Nov; 26(11):2237-2252. PubMed ID: 30728460 [TBL] [Abstract][Full Text] [Related]
16. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. Barnhill R; van Dam PJ; Vermeulen P; Champenois G; Nicolas A; Rawson RV; Wilmott JS; Thompson JF; Long GV; Cassoux N; Roman-Roman S; Busam KJ; Scolyer RA; Lazar AJ; Lugassy C J Pathol Clin Res; 2020 Jul; 6(3):195-206. PubMed ID: 32304183 [TBL] [Abstract][Full Text] [Related]
17. LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. Choi SK; Kim HS; Jin T; Moon WK Oncotarget; 2017 Feb; 8(7):11977-11989. PubMed ID: 28060764 [TBL] [Abstract][Full Text] [Related]
18. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Graziano F; Ruzzo A; Giacomini E; Ricciardi T; Aprile G; Loupakis F; Lorenzini P; Ongaro E; Zoratto F; Catalano V; Sarti D; Rulli E; Cremolini C; De Nictolis M; De Maglio G; Falcone A; Fiorentini G; Magnani M Pharmacogenomics J; 2017 Jun; 17(3):258-264. PubMed ID: 26927284 [TBL] [Abstract][Full Text] [Related]
19. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases. Nierop PM; Höppener DJ; Buisman FE; van der Stok EP; Galjart B; Balachandran VP; Jarnagin WR; Kingham TP; Shia J; Mauer M; Nordlinger B; Julié C; Groot Koerkamp B; Doukas M; Vermeulen PB; Grünhagen DJ; D'Angelica MI; Verhoef C J Pathol Clin Res; 2022 Jan; 8(1):48-64. PubMed ID: 34480530 [TBL] [Abstract][Full Text] [Related]
20. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]